AltheRx Presents Data on Improved Efficacy in an Experimental Combination of Beta3-Adrenoceptor Agonists and Antimuscarinics at American Urological Association Annual Meeting
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AltheRx Inc., a privately-held clinical development company, today announced results from a laboratory study in which combinations of beta3-adrenoceptor agonists, including its lead product candidate, solabegron, and several antimuscarinic agents were evaluated for their ability to inhibit bladder muscle contractions. The data were presented at the American Urological Association (AUA) Annual Meeting in San Diego, California (Abstract #283).
Help employers find you! Check out all the jobs and post your resume.
AltheRx Inc., a privately-held clinical development company, today announced results from a laboratory study in which combinations of beta3-adrenoceptor agonists, including its lead product candidate, solabegron, and several antimuscarinic agents were evaluated for their ability to inhibit bladder muscle contractions. The data were presented at the American Urological Association (AUA) Annual Meeting in San Diego, California (Abstract #283).
Help employers find you! Check out all the jobs and post your resume.